Company / Cash & Equivalents
Idexx Laboratories Cash & Equivalents History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$180.1M
FY2025
5-year range
$112.5M / $453.9M
FY2021-FY2025
Trend
-37.5%
vs FY2024
Sector context
#89 of 152
Health Care
What the data says
At $180M, Idexx Laboratories's cash & equivalents ranks #89 of 152 in the Health Care sector. Cash & Equivalents has fluctuated over the past 10 years, ranging from $90M in FY2019 to $454M in FY2023.
Based on SEC 10-K filings.
$180M in FY2025 with a 5-year CAGR of -14.1%.
Declined from $454M to $180M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +17.0%
- 5-Year CAGR
- -14.1%
- 10-Year CAGR
- -
Sector benchmark
#89 of 152 in Health CareTop 59% of 152This company $180.1M Sector average $1.2B
▼
-84.5% below sector average
Key checks
Key Insights
- 5-year CAGR of -14.1%, indicating a declining trend.
- In FY2025, cash & equivalents decreased 37.5% year-over-year.
- Ranks #89 out of 152 companies in the Health Care sector.
- Peak cash & equivalents was recorded in FY2023.
Company context
Key Data Points
- High Piotroski F-Score: 8/9 (strong financial health signals)
- Altman Z-Score 4.60 (safe zone, above 2.9 threshold)
- Strong profit margin: 24.6%
- High earnings quality (cash-backed earnings)
- Strong return on equity: 65.8%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $180.1M | -37.5% |
| FY2024 | $288.3M | -36.5% |
| FY2023 | $453.9M | +303.3% |
| FY2022 | $112.5M | -22.1% |
| FY2021 | $144.5M | -62.4% |
| FY2020 | $383.9M | +325.0% |
| FY2019 | $90.3M | -27.0% |
| FY2018 | $123.8M | -34.0% |
| FY2017 | $187.7M | +21.2% |
| FY2016 | $154.9M | +20.1% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026